| Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics T Di Desidero, P Orlandi, A Fioravanti, G Alì, C Cremolini, F Loupakis, ... Biochemical Pharmacology 164, 94-105, 2019 | 16 | 2019 |
| Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer T Di Desidero, P Orlandi, D Gentile, M Banchi, G Alì, C Kusmic, ... Pharmacological research 158, 104920, 2020 | 14 | 2020 |
| Antiangiogenic drugs in NASH: evidence of a possible new therapeutic approach P Orlandi, A Solini, M Banchi, MR Brunetto, D Cioni, L Ghiadoni, G Bocci Pharmaceuticals 14 (10), 995, 2021 | 12 | 2021 |
| Remarkable remission rate and long-term efficacy of upfront metronomic chemotherapy in elderly and frail patients, with diffuse large B-cell lymphoma G Bocci, S Pelliccia, P Orlandi, M Caridi, M Banchi, G Musuraca, ... Journal of Clinical Medicine 11 (23), 7162, 2022 | 11 | 2022 |
| Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer D Gentile, P Orlandi, M Banchi, G Bocci Medical Oncology 37, 1-15, 2020 | 9 | 2020 |
| Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma P Orlandi, M Banchi, G Alì, T Di Desidero, E Fini, G Fontanini, G Bocci Journal of Chemotherapy 33 (3), 198-202, 2021 | 7 | 2021 |
| All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma MC Cox, M Banchi, S Pelliccia, A Di Napoli, L Marcheselli, C Patti, ... Cancer chemotherapy and pharmacology 86, 841-846, 2020 | 7 | 2020 |
| Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients F Cucchiara, G Luci, N Giannini, FS Giorgi, P Orlandi, M Banchi, ... Pharmacological Research 181, 106290, 2022 | 5 | 2022 |
| Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells P Orlandi, D Gentile, M Banchi, F Cucchiara, T Di Desidero, C Cremolini, ... Investigational New Drugs 38, 92-98, 2020 | 5 | 2020 |
| Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, ... American Journal of Cancer Research 12 (7), 3347, 2022 | 4 | 2022 |
| Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report M Banchi, T Lanzolla, A Di Napoli, A Bandini, G Bocci, MC Cox Chemotherapy 69 (1), 40-44, 2024 | 3 | 2024 |
| A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients L Coltelli, G Allegrini, P Orlandi, C Finale, A Fontana, LC Masini, ... NPJ breast cancer 8 (1), 33, 2022 | 3 | 2022 |
| Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer M Banchi, P Orlandi, D Gentile, G Alì, E Fini, G Fontanini, G Francia, ... American Journal of Cancer Research 10 (7), 2120, 2020 | 3 | 2020 |
| New antiproliferative agents derived from tricyclic 3,4‐dihydrobenzo[4,5]imidazo[1,2‐a][1,3,5]triazine scaffold: Synthesis and pharmacological effects M Robello, S Salerno, E Barresi, P Orlandi, F Vaglini, M Banchi, ... Archiv der Pharmazie 355 (11), 2200295, 2022 | 2 | 2022 |
| Metronomic chemotherapy in pediatric oncology: from preclinical evidence to clinical studies M Banchi, E Fini, S Crucitta, G Bocci Journal of Clinical Medicine 11 (21), 6254, 2022 | 2 | 2022 |
| Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules M Banchi, MC Cox, G Bocci Cancer Letters 591, 216900, 2024 | | 2024 |
| Metronomic Chemotherapy in Elderly Patients A Bandini, PF Calabrò, M Banchi, P Orlandi, G Bocci Current Oncology Reports 26 (4), 359-376, 2024 | | 2024 |
| Pharmacodynamic biomarker analysis of gastrointestinal cancer patients treated with metronomic chemotherapy in the Italian COMET Trial ML Manca, D Prospero, S Darvishi, A Bandini, M Banchi, P Orlandi, ... Cancer Research 84 (6_Supplement), 5180-5180, 2024 | | 2024 |
| Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib P Orlandi, M Banchi, F Vaglini, M Carli, S Aringhieri, A Bandini, C Pardini, ... Biochemical Pharmacology 219, 115952, 2024 | | 2024 |
| Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase A Tinivella, M Banchi, G Gambacorta, F Borghi, P Orlandi, IR Baxendale, ... ACS pharmacology & translational science 6 (12), 1870-1883, 2023 | | 2023 |
